The Road to Cures Series: AML 2021: Strategies for Attack Before Diagnosis and After Remission – Module 2 of 5

Activity Overview

This activity provides an overview of important genetic mutations in acute myeloid leukemia and recent therapeutic advances.

This activity will cover the latest advancements in biology and treatments for acute myeloid leukemia, aggressive lymphoma, and myeloma. The development and practical applications for CAR T-cell therapy in blood cancers is presented. A review of data from the Leukemia & Lymphoma Society patient registry on SARS-CoV-2 vaccination and antibody response in patients with blood cancer provides a glimpse of unmet needs in this vulnerable patient population.

0.50 CE Credit(s)
Expires: March 9, 2023

Target Audience

This activity is designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals involved in the diagnosis and treatment of patients with blood cancers.

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Identify the impact of minimal residual disease (MRD) analysis and pre-leukemic clones on the treatment of acute leukemia

Activity Faculty

Roboz_300x400 (1)

Gail J. Roboz, MD

Professor, Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
Division of Hematology and Oncology
New York-Presbyterian Hospital
New York, NY

Subscribe

Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources